[(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Development of a selective and specific high affinity PET tracer, [(11)C]UCB-A, for the in vivo study of SV2A expression in humans. Radiochemistry and preclinical studies in rats and pigs including development of a tracer kinetic model to determine VT. A method for the measurement of percent intact tracer in plasma was developed and the radiation dosimetry was determined in rats.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Nucl. Med. Biol.

Title: Nuclear medicine and biology

ISSN (Electronic): 1872-9614

ISSN (Print): 0969-8051

Publication date (Electronic): Jun 2016

Volume: 43

Issue: 6

Affiliations

[1 ] Preclinical PET platform, Uppsala University, Uppsala, Sweden.

[2 ] Nuclear Medicine & PET, Uppsala University, Uppsala, Sweden; Medical Physics, Uppsala University Hospital, Uppsala, Sweden.

[3 ] Nuclear Medicine & PET, Uppsala University, Uppsala, Sweden; PET Centre, Uppsala University Hospital, Uppsala, Sweden.

[4 ] PET Centre, Uppsala University Hospital, Uppsala, Sweden.

[5 ] UCB Pharma, Brussels, Belgium.

[6 ] Preclinical PET platform, Uppsala University, Uppsala, Sweden; PET Centre, Uppsala University Hospital, Uppsala, Sweden. Electronic address: gunnar.antoni@pet.medchem.uu.se.

Article

Publisher Item ID: S0969-8051(15)30059-7

DOI: 10.1016/j.nucmedbio.2016.03.004

PubMed ID: 27260773

SO-VID: 63a441e7-8f3d-42c9-835e-08b2ae66b2a6

History

Keywords: Epilepsy,Preclinical PET,SV2A,[(11)C]UCB-A

Data availability:

Keywords: Epilepsy, Preclinical PET, SV2A, [(11)C]UCB-A

Comments

Comment on this article

scite_

Cited by 27

See all cited by

- Version 1